On Apr. 5, 2021, Anixa Biosciences announced that based on Proof of Concept animal study results, it was progressing to the next stage of development of its potential anti-viral therapy for Covid-19.

Anixa and OntoChem are seeking to develop an orally administrable, room-temperature stable, anti-viral therapy against SARS-CoV-2, the virus that causes Covid-19.